Figure 5.
Overallsurvival of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy, according to time of failure: relapse/progression between D0 and D30 (red), between D30 and D90 (blue), and after D90 (green).
Overallsurvival of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy, according to time of failure: relapse/progression between D0 and D30 (red), between D30 and D90 (blue), and after D90 (green).
